Q1

2020 BUSINESS RESULTS APRIL 23, 2020

AGENDA

INTRODUCTION AND COVID-19 UPDATE

Dave Ricks, Chairman and Chief Executive Officer

R&D UPDATE

Dan Skovronsky, M.D., Ph.D., Chief Scientific Officer

Q1 2020 FINANCIAL RESULTS

Josh Smiley, Chief Financial Officer

CLOSING REMARKS

Dave Ricks, Chairman and Chief Executive Officer

QUESTION AND ANSWER SESSION

SAFE HARBOR PROVISION

This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the effects of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including health care reform.

For additional information about the factors that affect the company's business, please see the company's latest Forms 10-K,10-Q, and any 8-Ks filed with the Securities and Exchange Commission.

The company undertakes no duty to update forward-looking statements except as required by applicable law

COVID-19 LILLY RESPONSE

MAINTAIN SUPPLY OF AND ACCESS TO MEDICINE

- All manufacturing facilities limited to essential personnel
- Additional precautions at all manufacturing sites
- Insulin Value Program caps monthly patient out-of-pocket at $35/Rx

REDUCE STRAIN ON MEDICAL SYSTEM

- Paused new clinical trial starts and enrollment for most programs
- Suspended in-person customer visits
- PPE donation and medical volunteers

DEVELOP TREATMENTS FOR COVID-19

- Antibody therapies through collaboration with AbCellera
- Baricitinib being assessed as anti-inflammatory approach
- Ang2 antibody in Phase 2 trial

KEEP EMPLOYEES SAFE

- Travel restrictions and remote work since early March
- Physical and mental health resources available

SUPPORT OUR COMMUNITIES

- #INThisTogether community awareness campaign
- Funding relief efforts and doubling employee match for COVID-19 giving
- Created drive-through COVID-19 testing facility
- Paid volunteer opportunities for employees

POTENTIAL COVID-19 TREATMENTS

Baricitinib

JAK1 / JAK2 inhibitor

- Part of NIAID's Adaptive COVID-19 Treatment Trial
- Anti-inflammatory activity hypothesized to be beneficial in treating COVID-19[1]
- Numerous investigator-led trials ongoing
- Initial results from NIAID trial expected in June

LY3127804

Angiopoietin 2 (Ang2) mAb

- Ang2 known to be elevated in patients with ARDS
- Phase 2 trial recently initiated
- Enrolling patients with pneumonia who are hospitalized due to COVID-19
- Results expected in June

Antibody Therapies

- Collaboration with AbCellera
- Assessing multiple fully human antibodies identified from early COVID-19 survivors
- Plan to submit IND by end of May

[1]The approved rheumatoid arthritis indication includes warnings about risk for developing serious infection

LILLY SELECT NME AND NILEX PIPELINE

APRIL 20, 2020

LEGEND

- NME
- NILEX
- * *Commercial Collaboration*

MOVEMENT SINCE January 27, 2020

- ACHIEVED MILESTONE
- REMOVAL

PHASE 1

- CD73 INHIBITOR Cancer
- N3PG Aβ MAB Alzheimer's
- KRAS G12C INHIBITOR Cancer
- GIP/GLP COAGONIST PEPTIDE Diabetes
- TAU MORPHOMER Alzheimer's
- ANGPTL3/8 MAB CVD
- SSTR4 AGONIST Pain
- GLP-1R NPA Diabetes
- TRPA1 ANTAGONIST Pain
- GGG TRI-AGONIST Diabetes
- D1 PAM II Dementia
- O-GLCNACASE INH Alzheimer's
- NOT DISCLOSED Cancer
- BTK INHIBITOR Cancer
- ERK INHIBITOR Cancer
- PD-1 MAB AGONIST Immunology
- SERD Cancer
- PACAP38 MAB Pain
- IL-2 CONJUGATE Immunology
- BTLA MAB AGONIST Immunology
- GDF 15 AGONIST Diabetes
- AUR A KINASE INHIBITOR Cancer
- OXYNTOMODULIN Diabetes
- IL-33 MAB Immunology
- CXCR1/2L MAB Immunology

PHASE 2

- TIRZEPATIDE NASH
- OLARATUMAB Pancreatic Cancer
- ANGIOPOIETIN 2 MAB COVID-19
- ABEMACICLIB Prostate Cancer
- CD200R MAB AGONIST Immunology
- AUTOMATED INSULIN DELIVERY SYS Diabetes
- BASAL INSULIN-FC Diabetes
- MEVIDALEN (D1 PAM) Dementia
- ZAGOTENEMAB (TAU MAB) Alzheimer's
- DONANEMAB (N3PG Aβ MAB) Alzheimer's

PHASE 3

- BARICITINIB COVID-19
- TIRZEPATIDE Obesity
- BARICITINIB Alopecia Areata
- BARICITINIB Systemic Lupus Erythematosus
- ABEMACICLIB Adjuvant Breast Cancer
- TANEZUMAB* Cancer Pain
- MIRIKIZUMAB Crohn's Disease
- MIRIKIZUMAB Ulcerative Colitis
- EMPAGLIFLOZIN* Heart Failure
- EMPAGLIFLOZIN* Chronic Kidney Disease
- SELPERCATINIB 1L Med Thyroid Cancer
- SELPERCATINIB 1L NSCLC
- TIRZEPATIDE Diabetes
- LEBRIKIZUMAB Atopic Dermatitis
- SOLANEZUMAB Preclinical AD
- MIRIKIZUMAB Psoriasis

REG REVIEW

- DULAGLUTIDE 3.0 / 4.5 mg
- BARICITINIB Atopic Dermatitis
- IXEKIZUMAB Non-Radiographic AxSpA
- CONNECTED CARE PREFILLED INSULIN PEN Diabetes
- TANEZUMAB* Osteoarthritis Pain
- SELPERCATINIB (RET INH) Cancer
- FLORTAUCIPIR Tau Imaging, *diagnostic*

APPROVED

- IXEKIZUMAB Pediatric Psoriasis
- LYUMJEV (URLi) Diabetes

REMOVED

- DACRA-089 Diabetes
- EMPAGLIFLOZIN* Type 1 Diabetes

POTENTIAL KEY EVENTS 2020

New since last update

Phase 3 Initiations

Tirzepatide CV Outcome Study (H2H vs. dulaglutide)
Selpercatinib for 1L NSCLC [3]
Selpercatinib for 1L medullary thyroid cancer [3]

Phase 3 Top-Line Data Disclosures

Empagliflozin CHF outcomes study HFrEF[1]
Tirzepatide for type 2 diabetes (first of five)
Baricitinib for atopic dermatitis (last two of five studies)
Mirikizumab in psoriasis (first of two studies)
Mirikizumab in ulcerative colitis (induction data)
Solanezumab for dominantly inherited Alzheimer's

Medical Meeting Presentations

Dulaglutide alternate doses for type 2 diabetes
LOXO-305 additional data from Phase 1/2 study

Regulatory Submissions

Baricitinib for atopic dermatitis (US/EU/J)
Tanezumab osteoarthritis pain (US[2]/ EU)
Selpercatinib for NSCLC and thyroid cancers (EU/J)[3]

Regulatory Actions

Dulaglutide alternate doses for type 2 diabetes (US/EU)
Dulaglutide REWIND CV outcomes study (US)
Empagliflozin + linagliptin + metformin XR for type 2 diabetes (US)[1]
Ultra rapid lispro for type 1 and type 2 diabetes (US/EU/J)
Flortaucipir as a PET imaging agent (US)
Galcanezumab for episodic cluster headache (EU)
Ixekizumab for non-radiographic axial spondyloarthritis (US/EU/J)
Ixekizumab for radiographic axial spondyloarthritis (EU)
Ramucirumab for 1L EGFR NSCLC cancer (US/EU/J)
Selpercatinib for NSCLC and thyroid cancers (US)

[1] in collaboration with Boehringer Ingelheim
[2] in collaboration with Pfizer
[3] occurred in Q4 2019

COVID-19 DYNAMICS IMPACTING OUTLOOK

REASONS FOR OPTIMISM

- Strong underlying fundamentals of business
- Transitory nature of delayed physician visits
- Unchanged unmet need for new and existing medicines
- Speed and agility of pharma industry working together to solve the problem
- Collaboration across public and private spheres

MID-TERM RISKS

- Reduction in New Therapy Starts most acute for newest brands
- Rise in unemployment and payer mix changes
- Inevitable fiscal pressure on government funded health care
- Delays in clinical trial activity

STRATEGIC DELIVERABLES

PROGRESS SINCE THE LAST EARNINGS CALL

Grow Revenue

- 15% revenue growth in Q1; 16% in constant currency
- Revenue growth driven by:
  - 22% volume growth
  - Key growth products accounted for over half of total revenue
  - Estimated COVID-19 impact ~$250 million

Improve Productivity

- Non-GAAP:
  - Gross margin was 80.3% (80.6% excluding FX impact on international inventories sold)
  - Operating margin was 30.1%

Create Long-Term Value

- Completed the acquisition of Dermira, Inc.
- Completed $0.5 billion in share repurchases
- Distributed nearly $0.7 billion via dividends

Speed Life-Changing Medicines

- Approval of ultra-rapid lispro Lyumjev in Europe and Japan
- Approval of Trulicity® REWIND study for a CV outcomes label claim in the U.S.
- Approval of Taltz ® for pediatric patients with moderate-to-severe plaque psoriasis

KEY EVENTS SINCE THE LAST EARNINGS CALL

COMMERCIAL

- Announced the **Lilly Insulin Value Program**, allowing anyone with commercial insurance and those without insurance to fill their monthly prescription of Lilly insulin for $35. The program covers most Lilly insulins including all **Humalog** ® formulations; and
- Announced participation in the Centers for Medicare & Medicaid Services (CMS) Part D Senior Savings Model that aims to improve the affordability of insulin for seniors in Medicare Part D. Beginning January 1, 2021, seniors in participating Medicare Part D insurance plans will see out-of-pocket costs for covered Lilly insulins reduced to no more than $35 per 30-day supply.

REGULATORY

- The U.S. Food and Drug Administration (FDA) approved **Trulicity** for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors;
- The FDA approved **Taltz** for the treatment of pediatric patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy;
- The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Lilly's new mealtime insulin, **Lyumjev**, for use in adults with type 1 and type 2 diabetes to reduce blood glucose;
- The FDA granted Fast Track designation to **empagliflozin**, part of our collaboration with Boehringer Ingelheim, to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease;
- The FDA granted Breakthrough Therapy designation to **baricitinib**, part of our collaboration with Incyte, for treatment of alopecia areata; and
- The FDA issued a complete response for **empagliflozin** 2.5 mg as an adjunct to insulin for adults with type 1 diabetes. The letter indicates that the FDA is unable to approve the application in its current form.

CLINICAL

- In the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study showed that **solanezumab** did not meet the primary endpoint. At this time, Lilly does not plan to pursue a submission for **solanezumab** in people with dominantly inherited Alzheimer's disease;
- **Mirikizumab** met the co-primary and key secondary endpoints in OASIS-1, a 52-week Phase 3 trial in moderate-to-severe plaque psoriasis. OASIS-2, the second Phase 3 trial will be completed later in 2020; and
- Completed the Phase 4 **Taltz** IXORA-R study in patients with moderate-to-severe psoriasis. As previously disclosed, **Taltz** achieved superiority compared to guselkumab on all primary and key secondary endpoints at week 12. Additionally, **Taltz** demonstrated non-inferiority to guselkumab on the final secondary endpoint at week 24.

BUSINESS DEVELOPMENT & OTHER

- Entered into an agreement with AbCellera to co-develop antibody products for the potential treatment and prevention of COVID-19. The collaboration will leverage AbCellera's rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly's global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies;
- Announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease modifying therapeutics in immuno-oncology and immuno-inflammation. The collaboration will study up to four novel preclinical targets identified by Sitryx; and
- Completed the acquisition of Dermira, Inc.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION; CERTAIN LINE ITEMS (UNAUDITED)

Millions; except per share data

	Q1 2020			
	GAAP Reported	Adjustments	Non-GAAP Adjusted	Non-GAAP Adjusted Change
TOTAL REVENUE	$5,860	-	**$5,860**	15%
GROSS MARGIN	79.3%	1.0%	**80.3%**	0.1pp
TOTAL OPERATING EXPENSE	3,054	(112)	**2,942**	7%
OPERATING INCOME	1,591	171	**1,762**	32%
OPERATING MARGIN	27.1%	3.0%	**30.1%**	3.9pp
OTHER INCOME (EXPENSE)	89	-	**89**	4%
EFFECTIVE TAX RATE	13.3%	0.3%	**13.6%**	0.7pp
NET INCOME	$1,457	142	**$1,599**	29%
EPS	**$1.60**	0.15	**$1.75**	32%

Note: Numbers may not add due to rounding; see slide 26 for a complete list of significant adjustments.

PRICE/RATE/VOLUME EFFECT ON REVENUE

Millions

	Q1 2020					
	Amount	Price	FX Rate	Volume	Total	CER
U.S.	$3,329	(4)%	—%	19%	15%	15%
EUROPE	1,061	(3)%	(3)%	24%	18%	21%
JAPAN	592	(3)%	1%	11%	9%	8%
CHINA	267	(64)%	(3)%	93%	27%	30%
REST OF WORLD	610	(2)%	(2)%	15%	12%	14%
TOTAL REVENUE	$5,860	(6)%	(1)%	22%	15%	16%

Note: Numbers may not add due to rounding.

CER = price change + volume change

KEY PRODUCTS DRIVING WW VOLUME GROWTH

Contribution to 22% Q1 WW Volume Growth



Numbers do not add due to rounding
Basaglar®, Jardiance®, and Tradjenta® are part of the Boehringer Ingelheim and Lilly Diabetes Alliance
* includes Baqsimi™, Basaglar, Cyramza®, Emgality®, Jardiance, Olumiant®, Taltz, Trulicity, Tyvyt®, and Verzenio®
** LOE: loss of exclusivity; includes Axiron®, Cialis®, Cymbalta®, Effient®, Evista®, Strattera®, and Zyprexa®

UPDATE ON KEY GROWTH PRODUCTS

Millions



BAQSIMI
- Approved July 2019 in U.S., NBRx SOM over 26% at end of Q1 2020

TYVYT
- Added to China's National Drug Reimbursement List in 2020

EMGALITY
- U.S. TRx SOM increased by 22pp vs. Q1 2019
- U.S. NBRx SOM 45% at the end of Q1 2020

VERZENIO
- Announced positive OS data in HR+, HER2- mBC in Q3 2019
- U.S. TRx grew over 43% vs. Q1 2019

OLUMIANT
- OUS Sales grew 70% vs. Q1 2019

TALTZ
- IL-17 class leader in U.S. NBRx and NTS SOM in dermatology
- Total molecule U.S. TRx grew nearly 37% vs. Q1 2019

BASAGLAR
- U.S. TRx 21% SOM at end of Q1 2020

JARDIANCE
- Market leader in U.S. TRx SOM 56% and NTS SOM over 62%
- Class growth strong in U.S. TRx +25% and NTS +35% vs. Q1 2019

CYRAMZA
- Robust WW sales growth +21% vs. Q1 2019

TRULICITY
- U.S. TRx leader with over 45% SOM
- U.S. GLP-1 class grew 33% vs. Q1 2019

Note: Jardiance is sold by Boehringer Ingelheim; Lilly records as revenue its share of Jardiance gross margin. Jardiance and Basaglar are part of the Boehringer Ingelheim and Lilly Diabetes Alliance.

CAPITAL ALLOCATION

Billions

Q1 2020 Capital Allocation



*After-tax (non-GAAP)

2020 GUIDANCE

	Prior	Updated	Comments
TOTAL REVENUE	$23.7 - $24.2 billion	unchanged	Reflects potential variability in timing and depth of healthcare utilization in Q2-Q4
GROSS MARGIN % (GAAP)	approx. 79%	unchanged	
GROSS MARGIN % (NON-GAAP)	approx. 81%	unchanged	
MKTG, SELLING & ADMIN.	$6.2 - $6.4 billion	unchanged	Reflects expected savings from reduced promotion and travel and investment in digital outreach
RESEARCH & DEVELOPMENT	$5.6 - $5.9 billion	unchanged	Reflects expected savings from pause in clinical trial activities and investment in potential COVID-19 treatments
OTHER INCOME/(EXPENSE)	$(250) – $(100) million	$(150) – $0 million	Updated to reflect Q1 equity portfolio gains
TAX RATE	approx. 15%	unchanged	
EARNINGS PER SHARE (GAAP)	$6.18 – $6.28	$6.20 – $6.40	Widened to reflect the uncertainty of the COVID-19 impact
EARNINGS PER SHARE (NON-GAAP)	$6.70 – $6.80	$6.70 – $6.90	Widened to reflect the uncertainty of the COVID-19 impact
OPERATING INCOME % (GAAP)	28%	unchanged	
OPERATING INCOME % (NON-GAAP)	31%	unchanged	

Assumes GAAP and non-GAAP shares outstanding 912 million

Updated FX assumptions of 1.11 (Euro), 108 (Yen) and 7.07 (Renminbi)

CLOSING REMARKS

Lilly Drive-Through COVID-19 Testing Facility

Lilly unites caring with discovery to create medicines that **make life better** for people around the world.

Lilly

SUPPLEMENTARY SLIDES

Q1 2020 PERFORMANCE SUMMARY

- Q1 2020 **volume-driven revenue growth** of 15% (16% in constant currency)
- Operating income as a % of revenue **improved nearly 400 bps** vs. Q1 2019
- Progress on our **innovation-based strategy**, including three approvals
- Deployed nearly $0.7 billion to shareholders via the dividend and completed $0.5 billion of share repurchases

Grow Revenue

Minimum average annual revenue growth of 7% in constant currency from 2015 through 2020

Improve Productivity

Excluding FX on int'l inventories sold, minimum non-GAAP operating margin % of revenue of 31% in 2020

Speed Life-Changing Medicines

- Potential to launch 20+ new molecules in 10 years (2014-2023)
- On average, could launch 2+ new indications or line extensions per year

Create Long-Term Value

- Fund existing marketed and pipeline products
- Bolster growth prospects via business development
- Annual dividend increases

2020 INCOME STATEMENT - REPORTED

Millions; except per share data

	Q1 2020	Change
TOTAL REVENUE	**$5,860**	15%
GROSS MARGIN	**79.3%**	1.7pp
TOTAL OPERATING EXPENSE*	**3,054**	(8)%
OPERATING INCOME	**1,591**	NM
OPERATING MARGIN	**27.1%**	NM
OTHER INCOME (EXPENSE)	**89**	4%
EFFECTIVE TAX RATE	**13.3%**	NM
NET INCOME	**$1,457**	NM
EARNINGS PER SHARE	**$1.60**	NM

* Includes research and development expense, marketing, selling and administrative expense, acquired in-process research and development charges, and asset impairment, restructuring and other special charges.
NM – not meaningful

NON-GAAP GROSS MARGIN % OF REVENUE



Individual quarter GM % of Revenue:	Q1 2018	Q2 2018	Q3 2018	Q4 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020
with FX effect on int'l inv sold	78.6%	79.8%	80.2%	80.6%	80.2%	81.0%	79.6%	79.9%	80.3%
w/o FX effect on int'l inv sold	81.5%	80.9%	80.3%	80.1%	80.2%	80.2%	78.9%	79.6%	80.6%

Note: The lines in the graph are moving annual totals (i.e. trailing 4 quarters) while the two rows of numbers are from specific quarters.
* 2018 has been reclassified to reflect divestiture of Elanco Animal Health in 2019.

NON-GAAP OPERATING MARGIN % OF REVENUE



Individual quarter GM % of Revenue:	Q1 2018	Q2 2018	Q3 2018	Q4 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020
with FX effect on int'l inv sold	29.3%	30.4%	28.7%	25.9%	26.2%	27.9%	28.6%	26.3%	30.1%
w/o FX effect on int'l inv sold	32.2%	31.5%	28.7%	25.4%	26.2%	27.2%	27.9%	25.9%	30.4%

Note: The lines in the graph are moving annual totals (i.e. trailing 4 quarters) while the two rows of numbers are from specific quarters.
* 2018 has been reclassified to reflect divestiture of Elanco Animal Health in 2019.

EFFECT OF FX ON 2020 RESULTS

Year-on-Year Growth

REPORTED	Q1 2020 With FX	Q1 2020 w/o FX
TOTAL REVENUE	15%	16%
COST OF SALES	7%	6%
GROSS MARGIN	17%	19%
OPERATING EXPENSE	(8)%	(7)%
OPERATING INCOME	NM	NM
EARNINGS PER SHARE	NM	NM

NON-GAAP	With FX	w/o FX
TOTAL REVENUE	15%	16%
COST OF SALES	14%	14%
GROSS MARGIN	15%	16%
OPERATING EXPENSE	7%	8%
OPERATING INCOME	32%	34%
EARNINGS PER SHARE	32%	34%

EPS RECONCILIATION

	Q1 2020	Q1 2019	Change
EPS (REPORTED)	**$1.60**	**$4.31**	**NM**
ASSET IMPAIRMENT, RESTRUCTURING, AND OTHER SPECIAL CHARGES	0.06	0.44	
AMORTIZATION OF INTANGIBLE ASSETS	0.05	0.04	
ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT	0.05	0.12	
LARTRUVO CHARGES		0.13	
REDUCED SHARES OUTSTANDING		0.03	
DISCONTINUED OPERATIONS		(3.74)	
EPS (NON-GAAP)	**$1.75**	**$1.33**	**32%**

Note: Numbers may not add due to rounding; see slide 26 for more details on these significant adjustments.

Q1 2020 INCOME STATEMENT NOTES

Q1 2020 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO ELIMINATE:

- amortization of intangible assets primarily associated with costs of marketed products acquired or licensed from third parties totaling $54.4 million (pretax), or $0.05 per share (after-tax);
- acquired in-process R&D charges totaling $52.3 million (pretax), or $0.05 per share (after-tax), related to business development activity other than a business combination, related to Sitryx; and
- asset impairment, restructuring and other special charges, primarily acquisition and integration costs as part of the closing of the acquisition of Dermira, totaling $64.1 million (pretax), or $0.06 per share (after-tax).

Q1 2019 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO ELIMINATE:

- discontinued operations of Elanco Animal Health business, substantially all the gain on the disposition, totaling a reduction of $3.74 per share (after-tax);
- assumption that the disposition of Elanco occurred at the beginning of the year and therefore include the benefit from the reduction in shares of common stock outstanding, totaling $0.03 per share (after-tax);
- amortization of intangible assets primarily associated with costs of marketed products acquired or licensed from third parties totaling $43.6 million (pretax), or $0.04 per share (after-tax);
- acquired in-process R&D charges totaling $136.9 million (pretax), or $0.12 per share (after-tax), related to business development activity other than a business combination, related to AC Immune SA and ImmuNext, Inc.;
- Charges related to the suspension of promotion of Lartruvo, totaling $96.7 million (pretax), or $0.13 per share (after-tax); and
- Charges primarily associated with the accelerated vesting of Loxo employee equity awards as a result of the closing of the acquisition of Loxo Oncology, totaling $411.8 million (pretax), or $0.44 per share (after-tax).

COMPARATIVE EPS SUMMARY 2019/2020

	1Q19	2Q19	3Q19	4Q19	2019	1Q20	2Q20	3Q20	4Q20	2020
Reported	4.31	1.44	1.37	1.64	8.89	1.60				
Non-GAAP	1.33	1.50	1.48	1.73	6.04	1.75				

Note: Numbers may not add due to rounding.

For a complete reconciliation to reported earnings, see slide 26 and our earnings press release dated April 23, 2020

Q1 2020 TRULICITY SALES INCREASED 40%

Millions

U.S. sales increased 40%
International sales increased 40%



U.S. TRx SOM and Market Volume



Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx 3MMA, weekly data March 27, 2020

Q1 2020 TALTZ SALES INCREASED 76%

Millions

U.S. sales increased 81%
International sales increased 62%



U.S. TRx Volume



Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx 3MMA, weekly data March 27, 2020
Note: TRx data is representative of the dermatology market

Q1 2020 BASAGLAR SALES INCREASED 21%

Millions

U.S. sales increased 16%
International sales increased 38%



U.S. TRx SOM and Market Volume



Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx 3MMA, weekly data March 27, 2020

Note: Basaglar is part of the Boehringer Ingelheim and Lilly Diabetes Alliance

Q1 2020 JARDIANCE SALES INCREASED 31%

Millions

U.S. sales increased 15%
International sales increased 57%



U.S. TRx SOM and Market Volume



Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx 3MMA, weekly data March 27, 2020
Note: Jardiance is part of the Boehringer Ingelheim and Lilly Diabetes Alliance

Q1 2020 CYRAMZA SALES INCREASED 21%

Millions

U.S. sales increased 19%
International sales increased 22%



Quarterly Sales by Major Geography



Note: Numbers may not add due to rounding.

Q1 2020 VERZENIO SALES INCREASED 72%

Millions

U.S. sales increased 38%
International sales were $59 million



U.S. NBRx Share of Market



Note: Numbers may not add due to rounding.

Source: IQVIA NPA NBRx 3MMA, weekly data March 27, 2020

Q1 2020 OLUMIANT SALES INCREASED 70%

Millions

U.S. sales increased 77%
International sales increased 70%



- Launched in the U.S. in July 2018
- Q1 sales driven by Germany and Japan
- Contributed 120bps to Q1 WW volume growth

Note: Numbers may not add due to rounding.

Q1 2020 EMGALITY SALES WERE $74 MILLION

Millions

U.S. sales were $67 million
International sales were $7 million



U.S. NBRx Share of Market



Note: Numbers may not add due to rounding.

Source: IQVIA NPA NBRx 3MMA, weekly data March 27, 2020

Q1 2020 TYVYT SALES WERE $57 MILLION

Millions

International sales were $57 million



- Launched in China in Q1 2019
- Part of Lilly collaboration with Innovent
- Contributed 210bps to Q1 WW volume growth

Note: Numbers may not add due to rounding.

Q1 2020 BAQSIMI SALES WERE $18 MILLION

Millions

U.S. sales were $16 million
International sales were $2 million



U.S. TRx Market Volume (000s)



Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx weekly data March 27, 2020

Q1 2020 HUMALOG SALES DECREASED 5%

Millions

U.S. sales decreased 11%
International sales increased 5%



U.S. TRx SOM



Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx 3MMA, weekly data March 27, 2020

SELECT TRIALS - JARDIANCE

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03594110^	Chronic Kidney Disease	EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)	3	6000	Composite primary outcome: Time to first occurrence of (i) kidney disease progression (defined as ESKD, a sustained decline in eGFR to <10 mL/min/1.73m², renal death, or a sustained decline of ≥40% in eGFR from randomization) or (ii) Cardiovascular death	Jun 2022	Jun 2022
NCT03332212	Heart Failure	A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin	3	72	Change from baseline to week 12 in PCr/ATP ratio in the resting state measured by 31P MRS.	May 2020	May 2020
NCT03057977	Heart Failure	EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)	3	3730	Composite primary endpoint - Time to first event of adjudicated CV (Cardiovascular) death or adjudicated HHF (Hospitalisation for Heart Failure) in patients with Heart Failure with reduced Ejection Fraction (HFrEF)	Jun 2020	Jul 2020
NCT03057951	Heart Failure	EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)	3	5982	Composite primary endpoint - Time to first event of adjudicated CV (Cardiovascular) death or adjudicated HHF (Hospitalisation for Heart Failure) in patients with Heart Failure with preserved Ejection Fraction (HFpEF)	Oct 2020	Nov 2020
NCT04157751	Heart Failure	A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure	3	500	The net clinical benefit, hierarchical composite endpoint composed of time to death, number of heart failure events (HFEs), time to first HFE, change in KCCQ-CSS from baseline after 90 days of treatment	Apr 2021	Jul 2021

In collaboration with Boehringer Ingelheim
^ also lists Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead)

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 15, 2020

SELECT TRIALS – LEBRIKIZUMAB

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04250337	Atopic Dermatitis	Safety and Efficacy of Lebrikizumab in Combination With Topical Corticosteroid in Moderate to Severe Atopic Dermatitis.	3	200	The primary efficacy endpoint is the percentage of patients with an IGA score of 0 or 1 and a reduction ≥2-points from Baseline to Week 16.	Feb 2021	May 2021
NCT04178967	Atopic Dermatitis	Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis	3	400	The primary efficacy endpoint is the percentage of patients with an IGA score of 0 or 1 and a reduction ≥2-points from Baseline to Week 16.	Jun 2021	Dec 2021
NCT04146363	Atopic Dermatitis	Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis	3	400	The primary efficacy endpoint is the percentage of patients with an IGA score of 0 or 1 and a reduction ≥2-points from Baseline to Week 16.	Jun 2021	Dec 2021
NCT04250350	Atopic Dermatitis	Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis	3	200	Number of adverse events from Baseline to Week 52	Nov 2021	Jan 2022

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

SELECT TRIALS – LYUMJEV (URLi)

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03740919	Type 1 Diabetes Mellitus	A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes	3	945	Change from Baseline in Hemoglobin A1c (HbA1c) (Prandial Dosing)	Jul 2021	Jul 2021
NCT03952130	Type 1 Diabetes Mellitus	A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes	3	350	Change from Baseline in Hemoglobin A1c (HbA1c)	May 2022	May 2022
NCT03952143	Type 2 Diabetes Mellitus	A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes	3	564	Change from Baseline in Hemoglobin A1c (HbA1c)	Feb 2021	Feb 2021

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

SELECT TRIALS – MIRIKIZUMAB

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03535194	Psoriasis	A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)	3	1443	Percentage of Participants with a Static Physician's Global Assessment (sPGA) of (0,1) with at Least a 2-point Improvement from Baseline	Mar 2020	Dec 2020
NCT03556202	Psoriasis	A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)	3	1816	Percentage of Participants with a Static Physician's Global Assessment Among Those who Entered the Study with a sPGA of 0,1(sPGA) of (0,1)	May 2024	May 2024
NCT03926130	Crohn's Disease	A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	3	1100	Percentage of Participants Achieving Endoscopic Response	Feb 2022	Jul 2023
NCT04232553	Crohn's Disease	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	3	778	Percentage of Participants Achieving Endoscopic Response	Nov 2023	Nov 2023
NCT03518086	Ulcerative Colitis	An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)	3	1160	Percentage of Participants in Clinical Remission	Sep 2020	Dec 2021
NCT03524092	Ulcerative Colitis	A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis	3	1044	Percentage of Participants in Clinical Remission	Jun 2021	Jun 2023
NCT03519945	Ulcerative Colitis	A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)	3	840	Percentage of Participants in Clinical Remission	Aug 2023	Aug 2023

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

SELECT TRIALS - OLUMIANT

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03899259	Alopecia Areata	A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata	3	476	Percentage of Participants Achieving Alopecia Areata Investigator Global Assessment (AA-IGA™) 0 or 1 with a ≥2 Point Improvement	Dec 2020	Mar 2022
NCT03570749	Alopecia Areata	A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata	2/3	725	Percentage of Participants Achieving Alopecia Areata Investigator Global Assessment (AA-IGA™) 0 or 1 with a ≥2 Point Improvement	Dec 2020	Mar 2022
NCT04280705^	Corona Virus Infection	Adaptive COVID-19 Treatment Trial (ACTT)	3	572	Time to recovery	Apr 2023	Apr 2023
NCT03616964	Systemic Lupus Erythematosus	A Study of Baricitinib in Participants With Systemic Lupus Erythematosus	3	750	Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (High Dose)	May 2021	Jun 2021
NCT03616912	Systemic Lupus Erythematosus	A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus	3	750	Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (High Dose)	May 2021	Jun 2021

In collaboration with Incyte
^ sponsored by National Institute of Allergy and Infectious Diseases (NIAID); baricitinib arm not yet reflected in clinicaltrials.gov

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

SELECT TRIALS – SELPERCATINIB

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03899792	Medullary Thyroid Cancer	A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors	1/2	100	To determine the safety of oral LOXO-292 in pediatric patients with advanced solid tumors: Dose limiting toxicities (DLTs)	Nov 2021	Oct 2022
NCT04211337	Medullary Thyroid Cancer	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer	3	400	Treatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR)	Feb 2023	Dec 2024
NCT03157128	Non-Small Cell Lung Cancer	Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer	1/2	970	Phase 1: Maximum tolerated dose (MTD)	Mar 2022	May 2022
NCT04194944	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer	3	400	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (with or without Pembrolizumab)	Dec 2023	Apr 2026
NCT04280081	Solid Tumor	A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation	2	75	Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR) by Independent Review Committee	May 2021	Apr 2023

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

SELECT TRIALS – SOLANEZUMAB

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT02008357^	Cognition Disorders	Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss	3	1150	Change from Baseline of the Preclinical Alzheimer Cognitive Composite (PACC)	Jul 2022	Jul 2022

^ also lists Alzheimer's Therapeutic Research Institute

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 18, 2020

SELECT TRIALS – TANEZUMAB

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT02609828	Neoplasm Metastasis	Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy.	3	155	Change from baseline in daily average pain intensity in index bone metastasis cancer pain site	Aug 2020	May 2021

In collaboration with Pfizer

*Molecule may have multiple indications; Indication is for pain associated with the condition listed
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, March 23, 2020

SELECT TRIALS – TIRZEPATIDE

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04166773	Non-alcoholic Steato-hepatitis	A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)	2	196	Percentage of Participants with Absence of NASH with no Worsening of Fibrosis on Liver Histology	Mar 2022	Mar 2022
NCT04184622	Overweight	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight	3	2400	Percent Change from Baseline in Body Weight	Feb 2022	Apr 2024
NCT03954834	Type 2 Diabetes Mellitus	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone	3	472	Change from Baseline in Hemoglobin A1c (HbA1c)	Oct 2020	Nov 2020
NCT03882970	Type 2 Diabetes Mellitus	A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes	3	1420	Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)	Dec 2020	Jan 2021
NCT04039503	Type 2 Diabetes	A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin	3	472	Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)	Jan 2021	Jan 2021
NCT03861039	Type 2 Diabetes Mellitus	A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes	3	441	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Feb 2021	Mar 2021
NCT03987919	Type 2 Diabetes	A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes	3	1872	Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)	Feb 2021	Mar 2021

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

SELECT TRIALS – TIRZEPATIDE (CONTINUED)

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03861052	Type 2 Diabetes	A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes	3	636	Change from Baseline in Hemoglobin A1c (HbA1c)	Mar 2021	Apr 2021
NCT03730662	Type 2 Diabetes Mellitus	A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk	3	1878	Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)	May 2021	Jun 2021
NCT04093752	Type 2 Diabetes	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)	3	956	Mean Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)	Feb 2022	Mar 2022
NCT04255433	Type 2 Diabetes Mellitus	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	3	12500	Time to First Occurrence of Death from Cardiovascular (CV) Causes, Myocardial Infarction (MI), or Stroke (MACE-3)	Oct 2024	Oct 2024

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

SELECT TRIALS – VERZENIO

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04031885	Metastatic Breast Cancer	A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer	4	300	Objective Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)	Apr 2021	Dec 2022
NCT03155997^	Breast Cancer	Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer	3	4580	Invasive Disease Free Survival (IDFS)	Apr 2021	Jun 2027

^ also lists NSABP Foundation Inc

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

SELECT TRIALS – EARLY PHASE COVID-19

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Angiopoietin 2 Mab	NCT04342897	COVID-19	A Study of LY3127804 in Participants With COVID-19	2	200	Number of Ventilator Free Days	Jul 2020	Jul 2020

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

SELECT TRIALS – EARLY PHASE DIABETES

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
GIP/GLP Coagonist Peptide	NCT04178733	Healthy	A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants	1	54	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Aug 2020	Aug 2020
GLP-1R NPA	NCT03929744	Healthy	A Study of LY3502970 in Healthy Participants	1	160	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug	Oct 2020	Oct 2020
ANGPTL3/8 MAB	NCT04052594	Dyslipidemias	A Study of LY3475766 in Healthy Participants	1	55	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Nov 2020	Nov 2020
Oxyntomodulin	NCT03928379	Diabetes Mellitus, Type 2	A Study of LY3305677 in Participants With Type 2 Diabetes	1	48	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug	Nov 2020	Nov 2020
Basal Insulin - FC	NCT04276428	Diabetes Mellitus, Type 2	A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus	1	27	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Nov 2020	Nov 2020
GGG Tri-Agonist	NCT04143802	Diabetes Mellitus, Type 2	A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)	1	75	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Dec 2020	Dec 2020
GDF15 Agonist	NCT03764774	Healthy	A Study of LY3463251 in Healthy Participants	1	143	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Dec 2020	Dec 2020

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

SELECT TRIALS – EARLY PHASE IMMUNOLOGY

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
CD200R MAB Agonist	NCT04159701	Chronic Spontaneous Urticaria	A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria	2	60	Mean Change from Baseline in Urticaria Activity Score Over 7 Days (UAS7)	Mar 2021	Aug 2021
BTLA MAB Agonist	NCT03933943	Lupus Erythematosus, Systemic	A Study of LY3361237 in Participants With Systemic Lupus Erythematosus	1	24	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug	Jan 2021	Jan 2021
IL-2 CONJUGATE	NCT04119557	Psoriasis	A Study of LY3471851 in Participants With Psoriasis	1	40	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Apr 2021	Apr 2021
IL-2 CONJUGATE	NCT04081350	Dermatitis, Atopic	A Study of LY3471851 in Participants With Eczema	1	40	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Apr 2021	Apr 2021
CD200R MAB Agonist	NCT03750643	Dermatitis, Atopic	A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis	1	128	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Jan 2022	Jan 2022
PD-1 Mab Agonist	NCT04152382	Psoriasis	A Safety Study of LY3462817 in Participants With Psoriasis	1	64	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Dec 2022	Dec 2022

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

SELECT TRIALS – EARLY PHASE NEURODEGENERATION

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Mevidalen (D1 PAM)	NCT03305809	Lewy Body Dementia	A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)	2	340	Change from Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB)	Jul 2020	Jul 2020
Donanemab (N3PG Aβ MAB)	NCT03367403	Alzheimer Disease	A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)	2	266	Change from Baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS) Score	Dec 2020	Nov 2021
Zagotenemab (Tau MAB)	NCT03518073	Alzheimer Disease (AD)	A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease	2	285	Change from Baseline on the integrated Alzheimer's Disease Rating Scale (iADRS)	Aug 2021	Oct 2021
O-GlcNAcase Inh.	NCT04106206	Healthy	A Safety Study of LY3372689 in Healthy Participants	1	54	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Observed by the Investigator During Study Drug Administration	Jun 2020	Jun 2020
D1 PAM II	NCT04014361	Healthy	A Study of LY3154885 in Healthy Participants	1	102	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Jan 2021	Jan 2021
Mevidalen (D1 PAM)	NCT04258826	Healthy	A Study to Evaluate LY3154207 on the Brain of Healthy Participants	1	34	Change from Baseline in Intrinsic Functional Connectivity Among Resting-State Networks of the Brain	Sep 2021	Sep 2021

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

SELECT TRIALS – EARLY PHASE ONCOLOGY

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Olaratumab	NCT02659020	Soft Tissue Sarcoma	A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma	1/2	310	Phase 1b: Recommended Phase 2 Dose of Olaratumab: Number of Participants with Dose Limiting Toxicity (DLT)	Jul 2020	Jul 2021
BTK Inhibitor	NCT03740529	Chronic Lymphocytic Leukemia	A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL	1/2	403	Maximum Tolerated Dose (MTD)	Oct 2020	Apr 2021
Olaratumab	NCT03086369	Metastatic Pancreatic Cancer	A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer	1/2	186	Number of Participants with Dose Limiting Toxicities (DLTs) Phase 1b	Jan 2021	Aug 2022
Aur A Kinase Inhibitor	NCT03898791	Small Cell Lung Cancer	A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer	1/2	64	Number of Participants with Dose Reductions	Feb 2021	Feb 2021
KRAS G12C Inhibitor	NCT04165031	Advanced Solid Tumor	A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation	1/2	230	Phase 1: Number or Participants with Dose Limiting Toxicities (DLTs)	Dec 2021	Dec 2021

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

SELECT TRIALS – EARLY PHASE ONCOLOGY (CONTINUED)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Olaratumab	NCT03126591^	Soft Tissue Sarcoma	A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma	1	41	Number of Participants with Olaratumab Dose Limiting Toxicities (DLTs)	Jul 2020	Oct 2020
Aur A Kinase Inhibitor	NCT03955939	Metastatic Breast Cancer	A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body	1	100	Number of Participants with Dose Reductions	Mar 2021	Mar 2021
CD73 Inhibitor	NCT04148937	Advanced Cancer	A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer	1	120	Number of Participants with Dose Limiting Toxicity (DLT)	Jun 2021	Dec 2022
ERK Inhibitor	NCT02857270	Advanced Cancer	A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer	1	272	Number of Participants with LY3214996 Dose Limiting Toxicities (DLTs)	Dec 2021	Dec 2021
SERD	NCT04188548	Breast Cancer	A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer	1	186	Number of Participants with Dose Limiting Toxicities (DLTs)	Oct 2022	Apr 2023
Aur A Kinase Inhibitor	NCT04106219^^	Neuroblastoma	A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma	1	71	Number of Participants with Dose Limiting Toxicities (DLTs)	Apr 2024	Apr 2025

^ also lists Merck Sharp & Dohme Corp.
^^ also lists New Approaches to Neuroblastoma Therapy Consortium (NANT) and Innovative Therapies for Children with Cancer in Europe (ITCC)

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

SELECT TRIALS – EARLY PHASE PAIN

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
TRPA1 Antagonist	NCT03977974	Healthy	A Study of LY3526318 in Healthy Participants	1	80	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Apr 2020	Apr 2020
SSTR4 Agonist	NCT04156750	Healthy	A Study of LY3556050 in Healthy Participants	1	51	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Jul 2020	Jul 2020

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020


Lilly